Bottom line
PHSTX vs XLV: the short answer
PHSTX (Putnam Global Health Care Fund) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
XLV is cheaper at 0.08% vs 1.04% — a difference of $96 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +6.5% for PHSTX (reporting dates differ).
PHSTX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
PHSTX vs XLV side by side
| PHSTX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Franklin Templeton | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.04% | 0.08% |
| Annual cost per $10k | $104 | $8 |
| 10-yr cost on $10k (prospectus) | $1,772 | $103 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0.02% |
| 1-yr return | −4.6% | +14.5% |
| 5-yr return (annualized) | +6.5% | +8.1% |
| 10-yr return (annualized) | +6.9% | +9.8% |
| Best quarter | +17.5% | +14.5% |
| Worst quarter | −12.3% | −12.7% |
| Net assets (fund) | $1.5B | $40.6B |
| Number of holdings | 115 | 65 |
| Portfolio turnover | 67% | 2% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PHSTX | XLV | Difference |
|---|---|---|---|
| 2024 | +1.3% | +2.5% | −1.2% |
| 2023 | +9.0% | +2.0% | +7.0% |
| 2022 | −4.7% | −2.1% | −2.7% |
| 2021 | +19.4% | +25.9% | −6.5% |
| 2020 | +15.9% | +13.3% | +2.7% |
| 2019 | +30.2% | +20.7% | +9.6% |
| 2018 | −0.6% | +6.3% | −6.9% |
| 2017 | +15.3% | +21.7% | −6.4% |
| 2016 | −11.7% | −2.8% | −8.9% |
Source: Fund prospectus bar charts
Holdings overlap
16 of PHSTX's top 25 holdings also appear in XLV's top 25.
| Holding | PHSTX | XLV |
|---|---|---|
| Eli Lilly & Co. | 13.15% | 16.51% |
| Johnson & Johnson | 8.46% | 10.64% |
| UnitedHealth Group, Inc. | 6.93% | 6.57% |
| AbbVie, Inc. | 6.05% | 7.74% |
| Merck & Co., Inc. | 4.88% | 5.52% |
| Thermo Fisher Scientific, Inc. | 4.50% | 3.24% |
| Intuitive Surgical, Inc. | 4.04% | 2.45% |
| CVS Health Corp. | 2.74% | 2.30% |
| Gilead Sciences, Inc. | 2.63% | 2.73% |
| McKesson Corp. | 2.14% | 1.58% |
| Cardinal Health, Inc. | 2.12% | 0.97% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 2.19% |
| Boston Scientific Corp. | 1.80% | 1.10% |
| Bristol-Myers Squibb Co. | 1.75% | 2.05% |
| HCA Healthcare, Inc. | 1.18% | 1.05% |
Source: SEC Form N-PORT
PHSTX top 10
- Eli Lilly & Co. — 13.15%
- Johnson & Johnson — 8.46%
- UnitedHealth Group, Inc. — 6.93%
- AbbVie, Inc. — 6.05%
- Novartis AG — 5.13%
- Merck & Co., Inc. — 4.88%
- AstraZeneca plc — 4.67%
- Thermo Fisher Scientific, Inc. — 4.50%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between PHSTX and XLV?
Which is cheaper, PHSTX or XLV?
Should I own both PHSTX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.